ProfileGDS5678 / 1439283_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 67% 72% 71% 73% 46% 67% 70% 60% 73% 66% 69% 60% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1779968
GSM967853U87-EV human glioblastoma xenograft - Control 24.0305767
GSM967854U87-EV human glioblastoma xenograft - Control 34.6114372
GSM967855U87-EV human glioblastoma xenograft - Control 44.5703571
GSM967856U87-EV human glioblastoma xenograft - Control 54.7219773
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1766446
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0980767
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3346270
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5778460
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7685473
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.954466
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2713769
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.626960
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0208767